Rigel Pharmaceuticals, Inc./$RIGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Ticker
$RIGL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
163
Website
RIGL Metrics
BasicAdvanced
$360M
9.68
$2.08
1.29
-
Price and volume
Market cap
$360M
Beta
1.29
52-week high
$25.42
52-week low
$15.50
Average daily volume
195K
Financial strength
Current ratio
2.2
Quick ratio
1.781
Long term debt to equity
461.981
Total debt to equity
544.229
Interest coverage (TTM)
5.56%
Profitability
EBITDA (TTM)
46.363
Gross margin (TTM)
76.94%
Net profit margin (TTM)
18.31%
Operating margin (TTM)
21.63%
Effective tax rate (TTM)
2.48%
Revenue per employee (TTM)
$1,250,000
Management effectiveness
Return on assets (TTM)
18.15%
Return on equity (TTM)
-567.43%
Valuation
Price to earnings (TTM)
9.68
Price to revenue (TTM)
1.753
Price to book
19.41
Price to tangible book (TTM)
-45.36
Price to free cash flow (TTM)
10.076
Free cash flow yield (TTM)
9.92%
Free cash flow per share (TTM)
200.18%
Growth
Revenue change (TTM)
70.16%
Earnings per share change (TTM)
-283.53%
3-year revenue growth (CAGR)
37.89%
10-year revenue growth (CAGR)
34.57%
3-year earnings per share growth (CAGR)
-25.12%
10-year earnings per share growth (CAGR)
-14.42%
Bulls say / Bears say
Rigel Pharmaceuticals reported a 40% increase in net product sales, totaling $33.5 million, primarily driven by strong sales of Tavalisse and Rezlidhia. (Investing.com)
The company entered into a strategic licensing agreement with Kissei Pharmaceuticals, granting Kissei exclusive rights to develop and commercialize Rezlidhia in Japan, the Republic of Korea, and Taiwan, potentially expanding its market reach. (Investing.com)
Rigel's stock reached a 52-week high of $17.5, reflecting a 120.29% increase over the past year, indicating strong investor confidence. (Investing.com)
The resignation of Dr. Brian Kotzin from the Board of Directors may raise concerns about leadership stability. (Investing.com)
Insider selling, including CEO Raul R. Rodriguez selling 4,952 shares, might signal potential concerns about the company's future performance. (American Banking and Market News)
Despite revenue growth, Rigel Pharmaceuticals is not currently profitable, with an operating income margin at -7.0% and a return on assets of -11.59%, which could be a concern for investors. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rigel Pharmaceuticals, Inc. stock?
Rigel Pharmaceuticals, Inc. (RIGL) has a market cap of $360M as of July 28, 2025.
What is the P/E ratio for Rigel Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Rigel Pharmaceuticals, Inc. (RIGL) stock is 9.68 as of July 28, 2025.
Does Rigel Pharmaceuticals, Inc. stock pay dividends?
No, Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Rigel Pharmaceuticals, Inc. dividend payment date?
Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Rigel Pharmaceuticals, Inc.?
Rigel Pharmaceuticals, Inc. (RIGL) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.